Definitive Healthcare (DH)
(Delayed Data from NSDQ)
$4.34 USD
+0.28 (6.90%)
Updated Aug 21, 2024 04:00 PM ET
After-Market: $4.34 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value A Growth F Momentum B VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DH 4.34 +0.28(6.90%)
Will DH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DH
Definitive Healthcare Corp. (DH) Meets Q2 Earnings Estimates
DH or PRVA: Which Is the Better Value Stock Right Now?
DH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bears are Losing Control Over Definitive Healthcare (DH), Here's Why It's a 'Buy' Now
5 Medical Info Systems Stocks to Buy for Stable Returns
Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates
Other News for DH
Definitive Healthcare: Poor Near-Term Outlook, But New CEO May Change Things
Definitive Healthcare price target lowered by $2 at Deutsche Bank, here's why
Definitive Healthcare price target lowered by $1 at Baird, here's why
Definitive Healthcare price target lowered by $2 at Barclays, here's why
Analysts Offer Insights on Healthcare Companies: Inspire Medical Systems (INSP), Definitive Healthcare Corp (DH) and Bicycle Therapeutics (BCYC)